Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share transactions and does not contain financial performance data.
Material Changes
The filing details specific transactions executed on October 24, 2006, by Abacus Corporate Trustees Limited, acting as trustee for the GlaxoSmithKline (US) Trust:
- Sale of 2,225 Ordinary Share ADRs on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of $55.65 per ADR.
- Transfer of 4,968 Ordinary Share ADRs to participants in the GlaxoSmithKline Share Value Plan.
These transactions were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the mechanics of the share plan transactions and the interests of directors Dr. J-P Garnier and Dr. M M Slaoui as potential beneficiaries of the trust.
Key Facts for Investor Verification
- Verify the total number of ADRs sold (2,225) and transferred (4,968) on October 24, 2006.
- Confirm the transaction price of $55.65 per ADR.
- Note that the transactions involve the GlaxoSmithKline (US) Trust, a grantor trust for employees or former employees of SmithKline Beecham Corporation.
- Recognize that Directors Dr. J-P Garnier and Dr. M M Slaoui hold interests in the trust shares similarly to other eligible employees.